Decreased serum aldolase B levels in patients with malignant tumors.
Serum aldolase B levels were determined in patients with malignant tumors using a radioimmunoassay method. Thirty-one of 52 patients with malignant tumors had decreased serum aldolase B levels of less than 20 ng/ml, whereas almost all of the normal subjects and the patients with liver diseases and other benign diseases showed serum aldolase B levels of more than 20 ng/ml. The decreased aldolase B levels observed in cancer patients were unrelated to the clinical stage of their disease. The decrease of aldolase B correlated well with the decrease of fructose-1-phosphate (F1P)-aldolase activity, but not with fructose-1,6-diphosphate (FDP)-aldolase activity in the sera of cancer patients. Mixing experiments did not identify an inhibitor of aldolase B in sera of cancer patients. Furthermore, recovery of serum aldolase B levels after successful surgical resection in cancer patients suggested that the low levels of aldolase B in sera of cancer patients was not of genetic origin. The mechanism responsible for the decrease of aldolase B in sera of cancer patients is unclear.
Asaka
M
M
Third Department of Internal Medicine, Hokkaido University School of Medicine, Sapporo, Japan.
Kimura
T
T
Nishikawa
S
S
Miyazuki
T
T
Alpert
E
E
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D005634:Fructose-Bisphosphate Aldolase / Q000097:blood*; D006801:Humans; D007527:Isoenzymes / Q000097:blood*; D008107:Liver Diseases / Q000201:enzymology; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000097:blood / Q000201:enzymology*; D011863:Radioimmunoassay; D013274:Stomach Neoplasms / Q000097:blood / Q000201:enzymology
D007527:Isoenzymes; D005634:Fructose-Bisphosphate Aldolase